<DOC>
	<DOC>NCT00990678</DOC>
	<brief_summary>The investigators want to investigate if HIV sero-positive males benefit from vitamin D supplementation. The study runs in 16 weeks and the participants are treated with one of three placebo controlled regimes (tablets): 1. Calcium 2. Calcium and 25-hydroxy-vitamin D 3. Calcium and 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D The endpoints are: - Serum vitamin D - Parathyroid hormone - ionized calcium - T-lymphocyte fractions (na√Øve, mature, Tregs) - Osteocalcin (bone metabolism)</brief_summary>
	<brief_title>Study of Vitamin D Supplementation to Male HIV Sero-positive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Seropositivity</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium, Dietary</mesh_term>
	<criteria>male HIVpositive at least 18 years old receiving HiglyActiveAntiRetroviral Therapy (HAART) hypercalcemia tuberculosis osteoporosis or other bone disease cancer with bone metastasis</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>humans</keyword>
	<keyword>vitamin D</keyword>
	<keyword>1-hydroxy-vitamin D</keyword>
	<keyword>Rocaltrol</keyword>
	<keyword>calcium</keyword>
	<keyword>complementary therapies</keyword>
</DOC>